Navigation Links
Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia

MONTREAL, Jan. 25, 2016 /PRNewswire/ - Milestone Pharmaceuticals Inc., a clinical stage cardiovascular company, announced today that the United States Adopted Name (USAN) Council recently adopted "etripamil" as the unique non-proprietary or generic name for MSP-2017.

The purpose of the United States Adopted Names Council is to serve the health professions in the United States by selecting simple, informative, and unique nonproprietary names for drugs by establishing logical nomenclature classifications based on pharmacological and/or chemical relationships.

"We are pleased to have etripamil approved as the generic name for MSP-2017," said Philippe Douville, Chief Executive Officer of Milestone. "The receipt of a USAN generic name is an exciting step forward as we continue to advance our NODE-1, Phase 2 clinical study with etripamil for paroxysmal supraventricular tachycardia. Etripamil could improve patients' quality of life by allowing them to terminate their PSVT episodes at home and minimize inpatient hospital treatments and/or emergency room visits."

About Etripamil (formerly MSP-2017)

Etripamil is being developed as a patient self-administered intranasal spray to terminate paroxysmal supraventricular tachycardia (PSVT) at the onset of episodes and is currently being evaluated in a Phase 2 clinical trial (NODE-1) in the United States and Canada. Etripamil is a novel and potent short-acting calcium channel antagonist intended for the treatment of patients with PSVT, a potentially debilitating cardiac arrhythmia.  Phase 1 results showed that etripamil had a rapid onset and reached pharmacologically relevant plasma levels within 5 minutes of administration. Etripamil is designed to be short-acting and metabolized quickly after resolution of the PSVT episode to avoid the potential complications of current long-term therapies.

Etripamil is intended to address an important unmet medical need in patients who demand a convenient, rapidly efficacious and safe self-administered product for the treatment of PSVT episodes in the home setting.  Information regarding the NODE-1 clinical study may be found at (study identifier NCT02296190).

About Paroxysmal Supraventricular Tachycardia

Paroxysmal supraventricular tachycardia is a condition that afflicts 1.7 million people and results in over 600,000 healthcare claims in the US alone per year. During a PSVT episode, patients may feel palpitations while heart rate increases dramatically and can exceed 200 beats per minute. Although the condition is not life threatening, it causes great concern on the part of the patient and generally results in an emergency trip to the hospital. In the emergency room, the patient is usually administered intravenous drugs and observed until symptoms disappear.

About Milestone Pharmaceuticals

Milestone is a clinical stage drug development company developing novel small molecule therapeutics based on clinically validated mechanisms of action for cardiovascular diseases. Milestone's lead product, etripamil, is a novel and potent short-acting calcium channel antagonist for the systemic treatment of PSVT in Phase 2 clinical studies. The Company has assembled a world-class drug development team and advisory board of key opinion leaders with significant cardiovascular expertise in cardiology, regulatory affairs, and drug development. For more information, please visit

SOURCE Milestone Pharmaceuticals Inc.
Copyright©2016 PR Newswire.
All rights reserved

Related biology technology :

1. QIAGEN Reaches Milestone With Portfolio of Master Collaboration Agreements for Pharma Companion Diagnostics
2. ChemWerth Hits Milestone with 50th DMF Available For Reference, Commits to Strong Pipeline of Future APIs
3. Blueline Bioscience announces milestone achievement by all Blueline Drug Target Program grant winners
4. The Genome Analysis Centre Announces an Important Milestone in Wheat Research
5. Regulus Achieves All Research Milestones in Collaboration with Biogen to Identify microRNA Biomarkers for Multiple Sclerosis
6. iLab/CORES Partnership Reaches Major Milestone
7. Latest Orphan Drug Designations for Developing Therapies for Rare Diseases Target New Treatments for Various Cancer Conditions - Biotech Company Reaches Two Major Milestones
8. VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
9. Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer
10. Phononic launches solid-state freezer achieving refrigeration milestone
11. Milestone Pharmaceuticals Closes US$17 Million Series B Financing to Complete Phase 2 Clinical Studies for MSP-2017
Post Your Comments:
(Date:6/19/2020)... ... , ... The Vitaspace project was founded by the famous Russian ... life and find a way (medicine or technology) that will help to preserve youth, ... scientists from all over the world, doctors, and all people who care. , The ...
(Date:6/3/2020)... ... 2020 , ... Thought Technology Ltd. is offering a free ... Dr. Inna Khazan will discuss the benefits of using mindfulness techniques with biofeedback. ... feelings, thoughts, and emotions they are having in the present moment and to ...
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... The ... and security leaders as the 2020 winners of the Women in Biometrics Awards ... sponsors IDEMIA , Biometric Update and the SIA Women in ...
(Date:5/21/2020)... (PRWEB) , ... May 20, 2020 , ... ... addition of Simon Prakash, who will serve as the company’s executive vice president ... a time when Exo is disrupting the medical imaging space, bringing more than ...
Breaking Biology Technology:
(Date:5/28/2020)... , ... May 27, 2020 , ... CrucialTrak, a global ... with New Jersey-based Critical Environments Group (CEG) to market and sell its complete line ... data center and IT environment infrastructure optimization solutions . , Brett Mason, ...
(Date:5/25/2020)... ... May 22, 2020 , ... Oxford Nanopore Technologies is in advanced development of ... that causes COVID-19. , The LamPORE assay is designed to be rapid, ... very large numbers of samples. Hardware and reagents sit outside current, squeezed supply ...
(Date:5/21/2020)... ... May 21, 2020 , ... Agility Orthopedics, home ... Greater Boston area, is pleased to announce a partnership with Dallas-based Simple Interact ... practices in the area, Agility Orthopedics is focused on speeding up patient workflows ...
Breaking Biology News(10 mins):